According to the performance forecast released on the evening of January 28, the net profit attributable to the shareholders of the listed company is expected to be RMB 900 million to RMB 1.3 billion in 2021, with a year-on-year decrease of 48.82% to 26.07%, which is mainly affected by the repeated impact of China’s centralized mining and foreign epidemic, superimposed with the increase of R & D expenditure, resulting in great changes in the overall performance of the company.
According to the introduction of Blue Sail Medical Co.Ltd(002382) , the overall performance of CB cardio holdings II Limited (hereinafter referred to as “CBCH II”) after the internal reorganization of the company decreased significantly. Among them, due to the repeated impact of China’s centralized procurement and foreign epidemics officially implemented from January 1, 2021, the increase of stent product sales failed to make up for the decline of price, and other coronary artery products have not been listed or in large quantities, resulting in a sharp decline in coronary artery business performance.
At the same time, Blue Sail Medical Co.Ltd(002382) ‘s heart valve business is still in the early stage of market development in Europe, and China’s first valve product has not been listed, resulting in limited performance growth of valve business. However, the company continues to increase R & D and clinical investment in valve and coronary artery products.
In addition, the performance in 2021 is superimposed with the impairment of capitalized development expenditure (mainly caused by the impact of the epidemic, the impairment caused by the loss of the commercial value of some invested clinical registration projects caused by changes in the market situation), internal restructuring and equity incentive expenses, resulting in a loss of about 600 million to 800 million yuan for CBCH II in 2021 (this data does not include the impact of goodwill impairment).
